Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
IPO
Biotech
Attovia's CEO aims to scratch itch opportunity with $289M IPO
Attovia plans to use the IPO haul to kick off two large ph. 2 studies for ATTO-1310, a biologic that blocks the itch-inducing interleukin-31.
Darren Incorvaia
Aug 5, 2026 7:00am
Latigo laces up for $247M IPO to fund rival to Vertex’s Journavx
Aug 4, 2026 7:55am
BlossomHill eyes $112M IPO harvest to fund Tagrisso challenger
Aug 3, 2026 9:18am
Apnimed’s IPO dream comes true with upsized $192M IPO
Jul 31, 2026 4:09am
Attovia, Braveheart and Vogenx seek more than $500M via IPOs
Jul 30, 2026 8:57am
Apnimed aspires for up to $160M IPO as sleep apnea launch nears
Jul 27, 2026 11:30am
